ArticleHuman gene therapy2010
Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells.
Article in Human gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Sex differences in vaccine-induced immunity in mice immunized with integrase-defective lentiviral vector delivering the SARS-CoV-2 Spike protein.Frontiers in immunology · 2026Article
- Article
- DC-targeting lentivectors for cancer immunotherapy.Immunotherapy advances · 2023Review
- The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers.NPJ vaccines · 2022Article
- Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization.Molecular therapy. Methods & clinical development · 2021Article
- Review
- Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice.Molecular therapy. Methods & clinical development · 2020Article
- Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.Frontiers in immunology · 2018Article
- Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Recent Advances in Lentiviral Vaccines for HIV-1 Infection.Frontiers in immunology · 2016Review
- Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response.EMBO molecular medicine · 2015Article
- Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation.Retrovirology · 2015Article
- Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.Molecular therapy. Methods & clinical development · 2015Article
- Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice.PloS one · 2014Article
- Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vector.PloS one · 2014Article
- Article
- Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines.Retrovirology · 2012Article
- Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.ISRN oncology · 2012Article
- The inside out of lentiviral vectors.Viruses · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Nonintegrating lentiviral vectors are being developed as a efficient and safe delivery system for both gene therapy and vaccine purposes. Several reports have demonstrated that a single immunization with integration-defective lentiviral vectors (IDLVs) delivering viral or tumor model antigens in mice was able to elicit broad and long-lasting specific immune responses in the absence of vector integration. At present, no evidence has been reported showing that IDLVs are able to expand preexisting immune responses in the human context. In the present study, we demonstrate that infection of human antigen-presenting cells (APCs), such as monocyte-derived dendritic cells (DCs) and macrophages with IDLVs expressing influenza matrix M1 protein resulted in effective induction of in vitro expansion of M1-primed CD8(+) T cells, as evaluated by both pentamer staining and cytokine production. This is the first demonstration that IDLVs represent an efficient delivery system for gene transfer and expression in human APCs, useful for immunotherapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.